To further assess the antiviral potential of VLPs-M8, we treated and infected hepatocellular carcinoma Huh-7 and lung carcinoma Calu-3 cells with the SARS-CoV-2 surrogate hCoV-229E and a VSV engineered to express the SARS-CoV-2 Spike and GFP (VSV-Spike), respectively. The gene discussed is CHMP5; the disease is lung carcinoma.